Adamas Pharmaceuticals (NASDAQ:ADMS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The brokerage currently has a $6.00 price target on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 9.49% from the company’s previous close.
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Other equities analysts have also recently issued reports about the company. Needham & Company LLC cut Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 5th. BidaskClub upgraded Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 15th. ValuEngine lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. HC Wainwright set a $40.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Finally, Mizuho lowered Adamas Pharmaceuticals from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $11.00 to $5.00 in a research report on Tuesday, March 5th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Adamas Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $20.25.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.05. The firm had revenue of $11.67 million during the quarter, compared to analysts’ expectations of $12.78 million. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. On average, analysts expect that Adamas Pharmaceuticals will post -3.87 earnings per share for the current fiscal year.
In other Adamas Pharmaceuticals news, CEO Gregory T. Went sold 6,319 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $7.99, for a total value of $50,488.81. Following the transaction, the chief executive officer now directly owns 176,291 shares in the company, valued at approximately $1,408,565.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 8,361 shares of company stock worth $66,816 over the last quarter. Corporate insiders own 24.90% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Advisors LLC boosted its position in Adamas Pharmaceuticals by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 16,709 shares of the specialty pharmaceutical company’s stock valued at $335,000 after buying an additional 5,940 shares during the last quarter. Vanguard Group Inc. boosted its position in Adamas Pharmaceuticals by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,008,448 shares of the specialty pharmaceutical company’s stock valued at $20,189,000 after buying an additional 18,879 shares during the last quarter. Teachers Advisors LLC boosted its position in Adamas Pharmaceuticals by 68.7% in the 3rd quarter. Teachers Advisors LLC now owns 61,024 shares of the specialty pharmaceutical company’s stock valued at $1,222,000 after buying an additional 24,859 shares during the last quarter. Broadfin Capital LLC boosted its position in Adamas Pharmaceuticals by 96.8% in the 4th quarter. Broadfin Capital LLC now owns 2,614,468 shares of the specialty pharmaceutical company’s stock valued at $22,328,000 after buying an additional 1,286,044 shares during the last quarter. Finally, Fosun International Ltd boosted its position in Adamas Pharmaceuticals by 228.3% in the 4th quarter. Fosun International Ltd now owns 196,959 shares of the specialty pharmaceutical company’s stock valued at $1,664,000 after buying an additional 136,959 shares during the last quarter. Hedge funds and other institutional investors own 88.03% of the company’s stock.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
See Also: Cryptocurrencies
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.